$74.8 Million

Novavax, Inc.

Follow-on Offering

Bookrunner, December 2022

Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax has developed a COVID-19 vaccine (“NVX-CoV2373”), and is developing an influenza vaccine candidate, a COVID-19-Influenza Combination vaccine candidate, and additional vaccine candidates, including for Omicron subvariants, and bivalent formulations with prototype vaccine (NVX-CoV2373). NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.